# Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia

> **NCT06045299** · PHASE3 · COMPLETED · sponsor: **Corxel Pharmaceuticals** · enrollment: 300 (actual)

## Conditions studied

- Presbyopia
- Near Vision
- Miosis
- Eye Diseases

## Interventions

- **DRUG:** Aceclidine+Brimonidine combination ophthalmic solution
- **DRUG:** Aceclidine ophthalmic solution
- **DRUG:** Placebo (Vehicle) ophthalmic solution

## Key facts

- **NCT ID:** NCT06045299
- **Lead sponsor:** Corxel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-27
- **Primary completion:** 2024-08-19
- **Final completion:** 2025-01-27
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2025-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06045299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06045299, "Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06045299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*